CRVO,CervoMed Inc. | Healthcare - www.financetom.com

Healthcare

CRVO

All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities

CervoMed Inc.CRVO

USD

- At close

USD

- Until the end

The complete list of US stocks

MAX

Overview >

% Change

Description >

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases.

It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery.

The company is based in Boston, Massachusetts.

Latest News >

National Bank on Thomson Reuters Selling FindLaw

Oct 4, 2024

01:04 PM EDT, 10/04/2024 (MT Newswires) -- Thomson Reuters ( TRI ) announced a deal this week to divest of FindLaw in a transaction expected to close during the fourth quarter, after regulatory approvals. In 2024, National Bank forecast Legal generating US$2,945 million in revenue and US$1,349M million in Adj. EBITDA. FindLaw represents about 10% of Legal's top line, analyst...

Sector Update: Health Care

Oct 4, 2024

01:42 PM EDT, 10/04/2024 (MT Newswires) -- Health care stocks eased Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both down 0.1%. The iShares Biotechnology ETF (IBB) rose 0.4%. In corporate news, Organon's (OGN) finasteride-containing Propecia product is under review in Europe over the ingredient's link to the risk of suicidal...

National Bank on DRI Healthcare's Casgevy Stream Acquisition

Oct 4, 2024

12:31 PM EDT, 10/04/2024 (MT Newswires) -- DRI Healthcare announced on October 3 that it acquired a portion of Editas Medicine payment rights under a non-exclusive license to Vertex Pharmaceuticals of Editas' Cas9 gene-editing technology for Casgevy for US$57 million. Casgevy is the only approved gene-edited cell therapy for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT), and is...

Market Chatter: GSK, Sanofi, CSL Awarded $72 Million From US Government to Boost Bird Flu Vaccine Production

Oct 4, 2024

12:58 PM EDT, 10/04/2024 (MT Newswires) -- GSK (GSK), Sanofi ( SNY ) , and CSL Ltd. were awarded $72 million by the US government to increase bird flu vaccine production, Bloomberg reported Friday, citing an interview with Dawn O'Connell, assistant secretary for preparedness and response at the US Department of Health and Human Services. The funding will be used...